| 产品描述: | MF63 is a selective and orally active inhibitor of mPGES-1. MF63 reduces the accumulation of PGE2, relieves pyresis, hyperalgesia, and inflammatory pain by inhibiting mPGES-1 |
| 靶点: |
mPGES-1 |
| 体内研究: |
MF63 (100 mg/kg;口服;单剂量) 可减少 KI (敲入 mPGES-1 基因) 小鼠气囊和大脑中 PEG2 的积累,并以剂量依赖的方式抑制 PEG2 的形成。 MF63 (10 mg/kg 和 100 mg/kg;口服;单剂量) 以剂量依赖的方式抑制 KI 小鼠中 LPS 诱导的痛觉过敏反应。 MF63 (0-150 mg/kg;口服;单剂量) 抑制豚鼠中 PEG2 合成、痛觉过敏、发热,并缓解慢性骨关节炎样疼痛。 MF63 (0-100 mg/kg;口服;每天两次,共 4 天) 对 KI 小鼠和非人类灵长类动物具有胃肠耐受性。 Animal Model: 10 to 12 weeks of KI and wild-type mice which injected LPS. Dosage: 10 mg/kg and 100 mg/kg. Administration: Oral gavage; single dose. Result: Inhibited the PGE2 accumulation in air pouch and brain of KI mice in a dose-dependent manner, and has selectively in the brain.Reduced the response of hyperalgesia by 50% at 10 mg/kg and 80% at 100 mg/kg in KI mice but without effecting wild-type mice. |
| 参考文献: |
1. Xu D, et al. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther. 2008 Sep;326(3):754-63. 2. Tuure L, et al. Regulation of gene expression by MF63, a selective inhibitor of microsomal PGE synthase 1 (mPGES1) in human osteoarthritic chondrocytes. Br J Pharmacol. 2020 Sep;177(18):4134-4146. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.64 ml |
13.199 ml |
26.398 ml |
| 5 mM |
0.528 ml |
2.64 ml |
5.28 ml |
| 10 mM |
0.264 ml |
1.32 ml |
2.64 ml |
| 50 mM |
0.053 ml |
0.264 ml |
0.528 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |